https://orcid.org/0000-0002-2486-4781
References
- Zepatier. Dosing information. [accessed 2022 May 15]. https://www.merckconnect.com/zepatier/dosing-administration/?#ssi-safety
- Zepatier (elbasvir + grazoprevir). [ accessed 2022 May 15]. https://www.catie.ca/zepatier-elbasvir-grazoprevir
- Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen B-Y, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.9.
- Kwo P, Gane E, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164–75.e4.
- Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño M-C, Hassanein T, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–45. doi:10.1016/S0140-6736(15)00349-9.
- Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–27.
- Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5:e1192–e207.
- Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham EB, Dumchev K, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019 ;114:150–66. doi:10.1111/add.14393.
- Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C-Y, Conway B, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Internal Med. 2016;165:625–34.16.
- Macias J, Morano LE, Tellez F, Granados R, Rivero- Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol. 2019;71:45–51.
- Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, et al. Direct-Acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction. 2018;113:868–82.
- Kramer JR, Puenpatom A, Cao Y, Yu X, El-Serag HB, Kanwal F. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 Jan 25. 1–9. doi:10.1080/00952990.2021.1983821.
- Zepatier. Patient information. [accessed 2022 May 20]. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_ppi.pdf